TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The firm said with a 4Q revenue beat preannounced the focus was the 2025 guide understanding what trends portend for the outlook and assessing if growth can re-accelerate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics price target lowered to $16 from $20 at BofA
- 10x Genomics price target lowered to $18 from $21 at Stifel
- 10x Genomics price target lowered to $12 from $14 at JPMorgan
- 10x Genomics price target lowered to $20 from $23 at Citi
- 10x Genomics price target lowered to $18 from $20 at Canaccord
Questions or Comments about the article? Write to editor@tipranks.com